Delivery Order SPE2DR25D2212-SPE2DR26FB9FW
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $1,595.00 to AmerisourceBergen Drug Corp for REPATHA 140 mg/mL SureClick auto-injectors. This competitive award, issued on November 13, 2025, with a completion date of November 14, 2025, represents a firm fixed-price transaction with no set-aside designation. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, fulfilled this order through its corporate office division as...
- The Defense Logistics Agency awarded a $7,700.94 firm fixed-price delivery order to AmerisourceBergen Drug Corp for REPATHA 140 mg/mL SureClick auto-injector pharmaceutical product, with an ultimate completion date of September 18, 2025. This delivery order, issued on September 17, 2025, represents a non-competitive award under the company's existing indefinite delivery contract vehicle with DLA and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania....
- The Defense Logistics Agency awarded a delivery order valued at $35,687.57 to AmerisourceBergen Drug Corp for REPATHA 140 mg/ml SureClick auto-injectors, a pharmaceutical product used in cardiovascular disease management. The contract, awarded on October 27, 2025, with an ultimate completion date of October 28, 2025, operates under a firm fixed-price structure with no set-aside designation, indicating competitive award. The place of performance is AmerisourceBergen's corporate office location in...
- The Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 19, 2025, for the supply of REPATHA 140 mg/mL SureClick auto-injectors with a ceiling value of $48,141.39. This competitively awarded, firm fixed price delivery order is not set-aside and has an ultimate completion date of August 20, 2025. The contract is performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company operates as a...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 11, 2025, for the supply of REPATHA 140 mg/ml SureClick auto-injectors, with a contract ceiling value of $31,271.18. This is a firm fixed-price delivery order with no set-aside designation, issued competitively to support federal medical procurement needs. The place of performance is AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania, with an ultimate completion date of...
- The Defense Logistics Agency awarded a $5,181.96 delivery order to AmerisourceBergen Drug Corp for REPATHA 140 MG/ML SureClick auto-injector pharmaceuticals, with an ultimate completion date of October 16, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and represents a single delivery order under AmerisourceBergen's larger Indefinite Delivery Contract vehicle with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December...
- AmerisourceBergen Drug Corp was awarded a delivery order valued at $30,136.70 by the Defense Logistics Agency (DLA) on August 26, 2025, for the supply of REPATHA 140 mg/ml SureClick auto-injectors. This firm fixed-price delivery order, with an ultimate completion date of August 27, 2025, represents a competitively awarded contract with no set-aside designation. The product will be delivered to the company's facility in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $20,467.51 to AmerisourceBergen Drug Corp for the supply of REPATHA 140 mg/ml SureClick auto-injectors, with an ultimate completion date of September 15, 2025. This firm fixed-price delivery order, awarded competitively without a set-aside designation, represents a discrete procurement from AmerisourceBergen's larger pharmaceutical supply relationship with the federal government. The product will be delivered to...
- AmerisourceBergen Drug Corp has been awarded a delivery order valued at $8,646.68 by the Defense Logistics Agency for the supply of REPATHA 140 mg/ml SureClick auto-injectors, with an ultimate completion date of November 4, 2025. This non-set-aside contract employs firm fixed pricing and represents a child delivery order under the company's larger indefinite delivery contract with DLA Troop Support Medical. The pharmaceutical products will be delivered to the company's corporate office...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $2,393.01 to AmerisourceBergen Drug Corp for the supply of REPATHA 140 MG/ML SureClick auto-injectors. The contract, awarded on August 20, 2025, with an ultimate completion date of August 21, 2025, represents a firm fixed price delivery order with no set-aside designation. This award was made under a competitive procurement process, reflecting AmerisourceBergen's capability to meet federal pharmaceutical supply requirements....
- SPE2DR25D2212Indefinite Delivery Contract
- SPE2DR25D2212-SPE2DR26FB9FWDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $15,662.94 to AmerisourceBergen Drug Corp for the supply of REPATHA 140 mg/mL SureClick auto-injectors. This competitive, non-set-aside contract utilizes firm fixed price terms and was executed on November 13, 2025, with an ultimate completion date of November 14, 2025. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a single transaction under the company's larger pharmaceutical supply relationship with the federal government. This award is issued under AmerisourceBergen's substantial Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999 and extending through December 2026. The IDC serves as a comprehensive global pharmaceutical support vehicle enabling the company to supply a broad range of medications, vaccines, and medical supplies to military healthcare systems worldwide. AmerisourceBergen's contract portfolio with DLA demonstrates its established capability to fulfill federal medical procurement requirements for specialty pharmaceuticals and brand-name medications across multiple therapeutic domains, supporting the Defense Health Agency and other government healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $15.7k | 11/13/25 |